News
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
The National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Kineret for the first-line treatment of the rare inflammatory disorder Still’s disease.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Kineret for the first-line treatment of the rare inflammatory disorder Still’s disease.